Pancreatic Cancer Research

ResearcherTranslational Genomics Research InstituteNo recent work listed

Marc F Botteman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2808-7163; OpenAlex author ID A5087184017. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 1 paper

Papers 7

  1. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with… Co-author DOI 10.1245/s10434-021-09816-z↗
  2. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literat… Co-author DOI 10.1097/mpa.0000000000001507↗
  3. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001563↗
  4. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Co-author DOI 10.1111/ajco.12999↗
  5. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Co-author DOI 10.2147/cmar.s163475↗
  6. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … Co-author DOI 10.1038/bjc.2017.67↗
  7. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. Last author DOI 10.3111/13696998.2014.903122↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michele Reni · 4 shared papers, 2014–2021 · strength 0.37
  2. Daniel D. Von Hoff · 3 shared papers, 2017–2020 · strength 0.26
  3. Andrew Eugene Hendifar · 2 shared papers, 2020–2021 · strength 0.22
  4. Amylou Constance Dueck · 2 shared papers, 2020–2021 · strength 0.22
  5. Do‐Youn Oh · 2 shared papers, 2020–2021 · strength 0.22
  6. Chung‐Pin Li · 2 shared papers, 2020–2021 · strength 0.22
  7. Margaret A. Tempero · 2 shared papers, 2020–2021 · strength 0.22
  8. Hanno B. Riess · 2 shared papers, 2020–2021 · strength 0.22
  9. Teresa Mercade Macarulla · 2 shared papers, 2020–2021 · strength 0.22
  10. Elena Gabriela Chiorean · 2 shared papers, 2018–2020 · strength 0.20
  11. Chrystal Ursula Louis · 1 shared paper, 2020 · strength 0.10
  12. David Goldstein · 1 shared paper, 2020 · strength 0.10
  13. Josep M. Tabernero · 1 shared paper, 2020 · strength 0.10
  14. Chee Khoon Lee · 1 shared paper, 2020 · strength 0.10
  15. Ramesh K. Ramanathan · 1 shared paper, 2020 · strength 0.10
  16. David Goldstein · 1 shared paper, 2018 · strength 0.10
  17. Rosemary Young · 1 shared paper, 2018 · strength 0.07
  18. Alfredo Romano · 1 shared paper, 2018 · strength 0.07
  19. Marion Harris · 1 shared paper, 2018 · strength 0.07
  20. Floris A. de Jong · 1 shared paper, 2017 · strength 0.06
  21. Jean‐Frédéric Blanc · 1 shared paper, 2017 · strength 0.06
  22. Li‐Tzong Chen · 1 shared paper, 2017 · strength 0.06
  23. Jens Thomas Siveke · 1 shared paper, 2017 · strength 0.06
  24. Uwe Pelzer · 1 shared paper, 2017 · strength 0.06
  25. Davide Melisi · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.